SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer
Status:
Terminated
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety of SU011248 and the highest dose of this
drug that can be given safely in combination with the chemotherapy drugs irinotecan and
cetuximab. Laboratory studies have shown that SU011248 may block the growth of blood vessels
in tumors, which may prevent tumors from growing any further. Other studies have demonstrated
the possibility that SU011248 may enhance the anti-tumor activity of other chemotherapy drugs
such as irinotecan and cetuximab.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute